INNOVATE Corp. (VATE) NYSE
12.17
+1.2(+10.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.17
+1.2(+10.94%)
Currency In USD
| Previous Close | 10.97 |
| Open | 11.03 |
| Day High | 12.2 |
| Day Low | 10.66 |
| 52-Week High | 12.24 |
| 52-Week Low | 3.75 |
| Volume | 95,828 |
| Average Volume | 30,059 |
| Market Cap | 166.18M |
| PE | -2.51 |
| EPS | -4.84 |
| Moving Average 50 Days | 6.15 |
| Moving Average 200 Days | 5.39 |
| Change | 1.2 |
Data not available
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- I
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
GlobeNewswire Inc.
Dec 16, 2025 1:05 PM GMT
MediBeacon® TGFRTM System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers begins in early 2026 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Co
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th
GlobeNewswire Inc.
Oct 22, 2025 8:05 PM GMT
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday, November 12, 2025, after market close. The Com